Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis

被引：10
作者：
Faron M. [1 ]
Chirica M. [1 ]
Tranchard H. [1 ]
Balladur P. [1 ]
de Gramont A. [1 ]
Afchain P. [1 ]
Andre T. [1 ]
Paye F. [1 ]
机构：
[1] Department of Digestive Surgery, AP-HP Hôpital Saint Antoine, rue du Faubourg Saint Antoine, Paris
来源：
Journal of Gastrointestinal Cancer | 2014年 / 45卷 / 3期
关键词：
Colorectal cancer; Liver metastasis; Chemotherapy;
D O I：
10.1007/s12029-014-9594-y
中图分类号：
学科分类号：
摘要：
PURPOSE: Whether the survival benefit of perioperative FOLFOX in patients with liver metastases of colorectal cancer (LMCRC) is provided by preoperative chemotherapy (CT), postoperative CT, or both remains unclear. This study aimed to evaluate, in patients with resectable LMCRC, the survival impact of preoperative and postoperative separately.; METHODS: Between 2000 and 2010, the 179 patients (126 men, age 61 ± 11 years) with initially resectable LMCRC, who underwent liver resection (LR) and were offered pre- and/or postoperative FOLFOX were included. Twenty-four (13%) patients did not receive CT, 27(15%) patients received only preoperative CT, 71 (40%) patients received only postoperative CT, and 57 (32%) patients received both pre- and postoperative CT.; RESULTS: Operative morbidity and mortality rates were 19 and 0.6%, respectively. At 1, 3, and 5 years, OS and DFS rates were 97, 66, 46 and 60, 32, and 24%, respectively. Postoperative FOLFOX was an independent predictor of increased OS (HR = 0.55 [95% CI, 0.35-0.87] p = 0.01) and DFS (HR = 0.54 [0.36-0.82] p = 0.0017), whereas the synchronous onset of the metastasis and the presence of radiographically occult liver metastases were independent predictors of poorer OS. Alternatively, preoperative FOLFOX had no significant influence on OS (HR = 0.96 [0.57-1.60] p = 0.83) or DFS (HR = 1.05 [0.66-1.66] p = 0.87).; CONCLUSIONS: The survival benefit of FOLFOX in patients with resectable LMCRC may be provided by postoperative rather than preoperative administration.
引用
收藏
页码：298 / 306
页数：8
相关论文
共 125 条
[1]  
De Haas RJ(2011)Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection Ann Surg 253 1069-79
[2]  
Wicherts DA(2000)Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938-47
[3]  
Andreani P(2006)Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 4976-82
[4]  
Pascal G(2002)Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study J Clin Oncol 20 1499-505
[5]  
Saliba F(1999)Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer N Engl J Med 341 2039-48
[6]  
Ichai P(1998)Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen) Ann Surg 228 756-62
[7]  
De Gramont A(2008)Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 1007-16
[8]  
Figer A(2010)Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252 774-87
[9]  
Seymour M(2012)Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 255 237-47
[10]  
Homerin M(2012)Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? J Surg Oncol 105 55-9
12345678910